stockrowAmarin Corporation PLC
AMRNHealthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.
- Revenue
- −20.4%
- EPS
- +103.1%
- Free cash flow
- +172.6%
Quarter to September 2026, against a year earlier
Follow AMRN
Alert me
Amarin Corporation PLC (AMRN) Return on invested capital
Amarin Corporation PLC's return on invested capital over the twelve months to 30 September 2026 was −16.6%, up 3.5 percentage points from fiscal 2025 (−20.0%). Over the past ten years it has ranged from −779.5% (fiscal 2015) to 3.14% (fiscal 2021); the current reading is higher than 45% of that period. That is below the Drug Manufacturers General industry median of 6.26% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −20.0% | 9.90 |
| FY2024 | −29.9% | (11.65) |
| FY2023 | −18.3% | 4.89 |
| FY2022 | −23.2% | (26.32) |
| FY2021 | 3.14% | 13.16 |
| FY2020 | −10.0% | (10.02) |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 480.23 |
| FY2016 | −480.2% | 299.31 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| OGN Organon & Co. compare | 6.26% |
| GRFS Grifols, S.A. compare | 4.76% |
| BIIB Biogen Inc. compare | 1.94% |
| NSRX Nasus Pharma Ltd. compare | 0.00% |
| SCLX Scilex Holding Company compare | 0.00% |
| AMRN Amarin Corporation PLC | −16.6% |
| MDCX Medicus Pharma Ltd compare | −2,497.5% |
| MIRA MIRA Pharmaceuticals, Inc. compare | −12,016.1% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)